Marker Therapeutics Secures $2.6M From FDA Through Its Orphan Products Clinical Trials Grants Program To Support Phase 1 Clinical Study Evaluating Lead Investigational MAR-T Cell Therapy, MT-601, In Pancreatic Cancer

Marker Therapeutics, Inc. (NASDAQ: MRKR) has secured $2.6 million from the FDA through its Orphan Products Clinical Trials grants program to support a Phase 1 clinical study of its lead investigational MAR-T cell therapy, MT-601, aimed at treating locally advanced unresectable pancreatic cancer. This funding is part of a competitive initiative to promote research for rare diseases, with only six out of 66 applications receiving support in fiscal year 2026.